Antares finally has its FDA nod for testosterone med Xyosted—and now it's revving up to take on AbbVie's AndroGel at a 20% list-price discount.
The approval case for Novo Nordisk’s oral diabetes candidate keeps on building, this time with new data in patients with kidney troubles.
A judge decided a $140 million AndroGel verdict against AbbVie was inconsistent and ordered a new trial in the fall.
Regeneron says a recent spike in a rare side effect for some Eylea patients is tied to some Becton Dickinson syringes that were distributed in the U.S.
Regeneron's Eylea has been a hit on the market for years. But now, the number of patients experiencing a rare side effect is climbing.